Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Delivery DevicesPackaging & Container

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753028

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753028

Vaccine Technologies

PUBLISHED:
PAGES: 573 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Vaccine Technologies Market to Reach US$80.5 Billion by 2030

The global market for Vaccine Technologies estimated at US$48.7 Billion in the year 2024, is expected to reach US$80.5 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Live-Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$23.3 Billion by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.3 Billion While China is Forecast to Grow at 11.9% CAGR

The Vaccine Technologies market in the U.S. is estimated at US$13.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.3% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.

Global "Vaccine Technologies" Market - Key Trends & Drivers Summarized

How Has the Pandemic Redefined the Vaccine Innovation Landscape?

The COVID-19 pandemic was a pivotal moment that accelerated the evolution of vaccine technologies in unprecedented ways, catalyzing global investment, innovation, and collaboration. The race to develop and deploy effective vaccines highlighted the potential of platforms like mRNA (Pfizer-BioNTech, Moderna), viral vectors (AstraZeneca, Johnson & Johnson), and protein subunits. These technologies not only proved their efficacy under extreme timelines but also established scalable, adaptable frameworks for combating future infectious diseases. mRNA technology, in particular, demonstrated the ability to generate rapid immune responses with high efficacy, opening doors for its application beyond COVID-19 into areas like influenza, Zika, RSV, HIV, and even cancer immunotherapy. This shift has drawn significant capital into biotech firms and pharmaceutical giants alike, leading to the establishment of modular vaccine platforms that can be quickly tailored for new pathogens. Government agencies, including the U.S. NIH and European EMA, are now working more closely with manufacturers to streamline approval pathways, emphasizing preparedness, real-time surveillance, and rapid-response capabilities.

What Role Are Emerging Markets and Cold Chain Innovations Playing?

Historically underserved regions such as Africa, Southeast Asia, and Latin America are becoming central to the expansion of vaccine technologies, thanks in large part to strategic investments in local manufacturing and distribution infrastructure. Global initiatives like COVAX, Gavi, and CEPI are playing instrumental roles in democratizing access to cutting-edge vaccines and enabling technology transfer. Regional vaccine production hubs are being established to reduce dependency on imports and ensure faster response during outbreaks. At the same time, advancements in cold chain logistics-including ultra-low temperature freezers, phase-change materials, and smart packaging-are enabling broader deployment of temperature-sensitive vaccines such as mRNA formulations. IoT-enabled tracking and predictive maintenance for storage units are also ensuring vaccine potency throughout the supply chain. These developments are helping to bridge the equity gap in global healthcare delivery and are laying the groundwork for mass immunization programs to be implemented more efficiently, reliably, and locally across emerging economies.

Can Cross-disciplinary Integration Unlock New Frontiers in Vaccine Development?

A profound transformation is underway as vaccine technologies become increasingly interdisciplinary, integrating data science, AI, and synthetic biology. AI and machine learning models are now routinely used to predict antigenic targets, optimize mRNA sequences, and simulate immune responses, thereby accelerating the preclinical development process. CRISPR and gene-editing tools are being harnessed to build next-generation vaccine vectors with enhanced precision and reduced side effects. Additionally, nanotechnology is revolutionizing vaccine delivery mechanisms, with lipid nanoparticles and polymer-based carriers improving bioavailability, cellular uptake, and storage stability. Combination vaccines, thermostable formulations, and needle-free delivery systems are also gaining momentum as they reduce logistical burdens and enhance patient compliance. The convergence of these disciplines is not only making vaccines more effective and accessible but also paving the way for personalized immunization strategies tailored to individual immune profiles. This integration represents a paradigm shift that positions vaccines as precision medical tools rather than one-size-fits-all solutions.

What Is Driving the Surging Growth in the Vaccine Technologies Market?

The growth in the vaccine technologies market is driven by several factors that cut across technological innovation, disease dynamics, regulatory evolution, and shifting consumer expectations. The emergence of novel pathogens, rising antimicrobial resistance, and recurring outbreaks of zoonotic diseases have underscored the need for robust vaccine pipelines and rapid production capabilities. Breakthroughs in mRNA, vector-based, and DNA-based platforms have reduced development timelines and enhanced scalability, making them attractive for both infectious and non-infectious disease applications. The widespread acceptance of adult immunization-once limited largely to children-is expanding target demographics, fueled by aging populations, global travel, and workplace mandates. Public awareness and vaccine literacy have surged post-pandemic, increasing demand for both routine and preventive vaccines. Regulatory agencies are becoming more agile, providing accelerated pathways for emergency use and fast-tracked approvals, thereby encouraging innovation and investment. Moreover, increased funding from governments, private investors, and global health alliances is enabling faster R&D, large-scale clinical trials, and infrastructure development. Together, these dynamics are transforming vaccine technologies into one of the most resilient and rapidly advancing sectors in global healthcare.

SCOPE OF STUDY:

The report analyzes the Vaccine Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines, Messenger RNA vaccines); Disease Indication (Infectious Diseases, Non-Infectious Diseases); Administration Route (Parenteral, Oral, Nasal); Age Group (Pediatric, Adult); Distribution Channel (Public Sector, Private Sector)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AstraZeneca
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech
  • CanSino Biologics
  • CSL Limited (Seqirus)
  • CureVac
  • GlaxoSmithKline (GSK)
  • Inovio Pharmaceuticals
  • Johnson & Johnson (Janssen)
  • Medicago
  • Merck & Co. (MSD)
  • Moderna
  • Novavax
  • Pfizer
  • Sanofi
  • Serum Institute of India
  • Sinopharm
  • Sinovac Biotech
  • VBI Vaccines

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP35959

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Vaccine Technologies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emergence of mRNA Platforms Spurs Innovation and Market Expansion
    • Rising Global Immunization Programs Propel Demand for Advanced Vaccine Technologies
    • COVID-19 Pandemic Legacy Strengthens Business Case for Rapid Vaccine Development
    • Government and NGO Funding Expands Addressable Market in Low-Income Regions
    • Increasing Zoonotic Disease Threats Accelerate R&D in Cross-Species Vaccines
    • Personalized and Therapeutic Vaccines Throw the Spotlight on Precision Medicine Applications
    • Technological Advancements in Cold Chain Logistics Drive Wider Vaccine Distribution
    • DNA, Viral Vector, and Protein Subunit Platforms Generate Opportunities for New Entrants
    • Regulatory Fast-Tracking and Emergency Use Authorizations Propel Growth of Novel Vaccines
    • Integration of AI and Big Data in Vaccine Discovery Sustains Competitive Innovation Cycles
    • Rising Vaccine Hesitancy and Misinformation Pose Public Health and Market Uptake Challenges
    • Global Health Security Initiatives Drive Demand for Scalable Vaccine Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Vaccine Technologies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Vaccine Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Live-Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Viral Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Viral Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Viral Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Messenger RNA vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Messenger RNA vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Messenger RNA vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Nasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Public Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Public Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Public Sector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Private Sector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Non-Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Non-Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Non-Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • JAPAN
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • CHINA
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 95: China Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • EUROPE
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Vaccine Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Europe 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • FRANCE
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 128: France Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: France 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 140: France Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: France 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • GERMANY
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Germany 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Germany 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Germany Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Germany 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Germany Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Germany 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Italy 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Italy 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 164: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Italy Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Italy 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 167: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Italy Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Italy 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Italy Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Italy 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 173: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: UK 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 176: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: UK Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: UK 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 179: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: UK Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: UK 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 182: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: UK Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: UK 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 185: UK Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UK Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: UK 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 188: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Spain Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Spain 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 191: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Spain Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Spain 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 194: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Spain Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Spain 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 197: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Spain Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Spain 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Spain Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Spain 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 203: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Russia Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Russia 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 206: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Russia Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Russia 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 209: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Russia Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Russia 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 212: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Russia Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Russia 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Russia Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Russia 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 218: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Europe Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Europe 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Rest of Europe Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Rest of Europe 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Europe Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Europe 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Europe Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Europe 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Europe 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Asia-Pacific Historic Review for Vaccine Technologies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Asia-Pacific Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Asia-Pacific Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Asia-Pacific 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 251: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Australia Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Australia 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 254: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Australia Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Australia 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 257: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Australia Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Australia 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 260: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Australia Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Australia 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Australia Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Australia 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • INDIA
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 266: India Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: India Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: India 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 269: India Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: India Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: India 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 272: India Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: India Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: India 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 275: India Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: India Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: India 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 278: India Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: India Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: India 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 281: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: South Korea Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: South Korea 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 284: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: South Korea Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: South Korea 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 287: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: South Korea Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: South Korea 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 290: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: South Korea Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: South Korea 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: South Korea Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: South Korea 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 296: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 311: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 312: Latin America Historic Review for Vaccine Technologies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Latin America 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 314: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Latin America Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Latin America 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 317: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Latin America Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Latin America 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Latin America Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Latin America 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Latin America Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Latin America 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Latin America Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Latin America 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 329: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Argentina Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Argentina 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 332: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Argentina Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Argentina 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 335: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Argentina Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Argentina 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 338: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Argentina Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Argentina 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Argentina Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Argentina 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 344: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Brazil Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Brazil 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 347: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Brazil Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Brazil 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 350: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Brazil Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Brazil 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 353: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Brazil Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Brazil 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Brazil Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Brazil 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 359: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Mexico Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Mexico 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 362: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Mexico Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Mexico 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 365: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Mexico Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Mexico 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 368: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Mexico Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Mexico 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Mexico Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Mexico 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 374: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Latin America Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Latin America Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Latin America Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Latin America Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Latin America 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 389: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 390: Middle East Historic Review for Vaccine Technologies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Middle East 15-Year Perspective for Vaccine Technologies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 392: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Middle East Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Middle East 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 395: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Middle East Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Middle East 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Middle East Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Middle East 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Middle East Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Middle East 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Middle East Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Middle East 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 407: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Iran Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Iran 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 410: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Iran Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Iran 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 413: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Iran Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Iran 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 416: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Iran Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Iran 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Iran Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 421: Iran 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 422: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Israel Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 424: Israel 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 425: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Israel Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 427: Israel 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 428: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Israel Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 430: Israel 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 431: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Israel Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 433: Israel 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Israel Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 436: Israel 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 437: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Saudi Arabia Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 439: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Saudi Arabia Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 442: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Saudi Arabia Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 445: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 447: Saudi Arabia Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 448: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 451: Saudi Arabia 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 452: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 453: UAE Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 454: UAE 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 455: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 456: UAE Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 457: UAE 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 458: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 459: UAE Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 460: UAE 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 461: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 462: UAE Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 463: UAE 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 465: UAE Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 466: UAE 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 467: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 468: Rest of Middle East Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 469: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 471: Rest of Middle East Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 472: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 474: Rest of Middle East Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 475: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Rest of Middle East Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 478: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 481: Rest of Middle East 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030
  • AFRICA
    • Vaccine Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 482: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Africa Historic Review for Vaccine Technologies by Technology - Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 484: Africa 15-Year Perspective for Vaccine Technologies by Technology - Percentage Breakdown of Value Sales for Live-Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Viral Vector Vaccines and Messenger RNA vaccines for the Years 2015, 2025 & 2030
    • TABLE 485: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Africa Historic Review for Vaccine Technologies by Administration Route - Oral, Nasal and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 487: Africa 15-Year Perspective for Vaccine Technologies by Administration Route - Percentage Breakdown of Value Sales for Oral, Nasal and Parenteral for the Years 2015, 2025 & 2030
    • TABLE 488: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Africa Historic Review for Vaccine Technologies by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 490: Africa 15-Year Perspective for Vaccine Technologies by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 491: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 492: Africa Historic Review for Vaccine Technologies by Distribution Channel - Public Sector and Private Sector Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 493: Africa 15-Year Perspective for Vaccine Technologies by Distribution Channel - Percentage Breakdown of Value Sales for Public Sector and Private Sector for the Years 2015, 2025 & 2030
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 495: Africa Historic Review for Vaccine Technologies by Disease Indication - Infectious Diseases and Non-Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 496: Africa 15-Year Perspective for Vaccine Technologies by Disease Indication - Percentage Breakdown of Value Sales for Infectious Diseases and Non-Infectious Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!